CRTHF (CARsgen Therapeutics Holdings) Other Financing: $10.67 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRTHF CARsgen Therapeutics Holdings Ltd CRTHF
21 GF Score
Price $1.91
! 3 Warning Signs
View Full Analysis

What is CARsgen Therapeutics Holdings Other Financing?

CARsgen Therapeutics Holdings CRTHF 21 Other Financing is $10.67 Mil as of Dec. 2025. GuruFocus rates CRTHF with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

CARsgen Therapeutics Holdings's Other Financing for the six months ended in Dec. 2025 was $-0.39 Mil.

CARsgen Therapeutics Holdings's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $10.67 Mil.

CARsgen Therapeutics Holdings Other Financing Historical Data

* Premium members only.

The historical data trend for CARsgen Therapeutics Holdings's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARsgen Therapeutics Holdings Other Financing Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -15.27 -2.28 -0.70 -0.80 10.88

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.14 -0.66 11.06 -0.39
CRTHF
21GF Score
CARsgen Therapeutics Holdings Ltd CRTHF
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CARsgen Therapeutics Holdings Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $10.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $10.67 Mil mean?
CARsgen Therapeutics Holdings (CRTHF) has a Other Financing of $10.67 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for CARsgen Therapeutics Holdings and its competitors.
Is CARsgen Therapeutics Holdings' Other Financing too high?
CARsgen Therapeutics Holdings' current Other Financing is $10.67 Mil. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' Other Financing compare to VRTX and REGN?
CARsgen Therapeutics Holdings' Other Financing of $10.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for CARsgen Therapeutics Holdings and its competitors. CARsgen Therapeutics Holdings's current Other Financing is $10.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (CRTHF) has a current Other Financing of $10.67 Mil. The current Other Financing is $10.67 Mil. CARsgen Therapeutics Holdings' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (CRTHF), the current Other Financing is $10.67 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARsgen Therapeutics Holdings Business Description

Other Exchanges 02171:Hong Kong
Address No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
21GF Score

Get the complete analysis for CRTHF

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.91
Price